Tags

Type your tag names separated by a space and hit enter

Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial.
Int J Geriatr Psychiatry. 2005 Jun; 20(6):559-69.IJ

Abstract

BACKGROUND

There have been very limited investigations of cholinesterase inhibitor therapy in more advanced stages of Alzheimer's disease (AD). The efficacy and safety of donepezil were evaluated in post hoc analyses of a subgroup of patients with more severe AD (standardized Mini-Mental State Examination [sMMSE] score 5-12) within a randomized, placebo-controlled trial in moderate to severe AD (MSAD study). Additional analyses examined whether donepezil's treatment effects were consistent across the full range of baseline AD severity studied (sMMSE score 5-17).

METHODS

Patients with moderate to severe AD (n = 290) who were living in the community or in assisted living facilities received donepezil or placebo for 24 weeks; n = 145 in the more severe AD subgroup. The primary outcome measure was the Clinician's Interview-Based Impression of Change (CIBIC-plus) with secondary outcomes including the sMMSE, Severe Impairment Battery, Neuropsychiatric Inventory, and Disability Assessment for Dementia. Analysis of Variance and Analysis of Covariance models tested for treatment x disease severity interaction in the full MSAD study sample.

RESULTS

CIBIC-plus scores for donepezil patients were significantly improved compared with placebo for each time-point, with a 0.70 mean treatment difference at Week 24 last observation carried forward (LOCF; p = 0.0002). Significant differences favoring donepezil were noted at Week 24 LOCF for all secondary measures. There were no treatment x severity interactions for any of the efficacy measures.

CONCLUSIONS

In this analysis, donepezil had significant benefits over placebo on global, cognitive, functional, and behavioral measures in a subgroup of patients with more severe AD. Furthermore, the treatment effects of donepezil were not driven by a particular stratum within the moderate to severe dementia range.

Authors+Show Affiliations

Feldman H
Division of Neurology, University of British Columbia, Clinic for Alzheimer's Disease and Related Disorders, Vancouver, BC, Canada. hfeldman@interchange.ubc.ca
Gauthier S
No affiliation info available
Hecker J
No affiliation info available
Vellas B
No affiliation info available
Xu Y
No affiliation info available
Ieni JR
No affiliation info available
Schwam EM
No affiliation info available
Donepezil MSAD Study Investigators Group
No affiliation info available

MeSH

AgedAged, 80 and overAlzheimer DiseaseCholinesterase InhibitorsDisability EvaluationDonepezilDouble-Blind MethodFemaleHumansIndansMaleMiddle AgedNeuropsychological TestsNootropic AgentsPiperidinesPsychiatric Status Rating ScalesTreatment Outcome

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15920715

Citation

Feldman, Howard, et al. "Efficacy and Safety of Donepezil in Patients With More Severe Alzheimer's Disease: a Subgroup Analysis From a Randomized, Placebo-controlled Trial." International Journal of Geriatric Psychiatry, vol. 20, no. 6, 2005, pp. 559-69.
Feldman H, Gauthier S, Hecker J, et al. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial. Int J Geriatr Psychiatry. 2005;20(6):559-69.
Feldman, H., Gauthier, S., Hecker, J., Vellas, B., Xu, Y., Ieni, J. R., & Schwam, E. M. (2005). Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial. International Journal of Geriatric Psychiatry, 20(6), 559-69.
Feldman H, et al. Efficacy and Safety of Donepezil in Patients With More Severe Alzheimer's Disease: a Subgroup Analysis From a Randomized, Placebo-controlled Trial. Int J Geriatr Psychiatry. 2005;20(6):559-69. PubMed PMID: 15920715.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial. AU - Feldman,Howard, AU - Gauthier,Serge, AU - Hecker,Jane, AU - Vellas,Bruno, AU - Xu,Yikang, AU - Ieni,John R, AU - Schwam,Elias M, AU - ,, PY - 2005/5/28/pubmed PY - 2005/10/18/medline PY - 2005/5/28/entrez SP - 559 EP - 69 JF - International journal of geriatric psychiatry JO - Int J Geriatr Psychiatry VL - 20 IS - 6 N2 - BACKGROUND: There have been very limited investigations of cholinesterase inhibitor therapy in more advanced stages of Alzheimer's disease (AD). The efficacy and safety of donepezil were evaluated in post hoc analyses of a subgroup of patients with more severe AD (standardized Mini-Mental State Examination [sMMSE] score 5-12) within a randomized, placebo-controlled trial in moderate to severe AD (MSAD study). Additional analyses examined whether donepezil's treatment effects were consistent across the full range of baseline AD severity studied (sMMSE score 5-17). METHODS: Patients with moderate to severe AD (n = 290) who were living in the community or in assisted living facilities received donepezil or placebo for 24 weeks; n = 145 in the more severe AD subgroup. The primary outcome measure was the Clinician's Interview-Based Impression of Change (CIBIC-plus) with secondary outcomes including the sMMSE, Severe Impairment Battery, Neuropsychiatric Inventory, and Disability Assessment for Dementia. Analysis of Variance and Analysis of Covariance models tested for treatment x disease severity interaction in the full MSAD study sample. RESULTS: CIBIC-plus scores for donepezil patients were significantly improved compared with placebo for each time-point, with a 0.70 mean treatment difference at Week 24 last observation carried forward (LOCF; p = 0.0002). Significant differences favoring donepezil were noted at Week 24 LOCF for all secondary measures. There were no treatment x severity interactions for any of the efficacy measures. CONCLUSIONS: In this analysis, donepezil had significant benefits over placebo on global, cognitive, functional, and behavioral measures in a subgroup of patients with more severe AD. Furthermore, the treatment effects of donepezil were not driven by a particular stratum within the moderate to severe dementia range. SN - 0885-6230 UR - https://www.unboundmedicine.com/medline/citation/15920715/Efficacy_and_safety_of_donepezil_in_patients_with_more_severe_Alzheimer's_disease:_a_subgroup_analysis_from_a_randomized_placebo_controlled_trial_ DB - PRIME DP - Unbound Medicine ER -